Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terbutaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.81 |
| ▸ | LMNA | P02545 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.97 |
| ▸ | CASP7 | P55210 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | BLM | P54132 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.97 |
| ▸ | CASP1 | P29466 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.81 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terbutaline SCHEMBL41870 | 0.98 | LMNA (1.00) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL3937997 | 0.98 | LMNA (1.00) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL9614480 | 0.98 | LMNA (1.00) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL5178614 | 0.98 | LMNA (1.00) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL26462 | 0.98 | LMNA (1.00) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL9524623 | 0.97 | LMNA (0.97) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL8030115 | 0.97 | LMNA (0.97) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL11220263 | 0.97 | LMNA (0.97) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL10783388 | 0.97 | LMNA (0.97) | LMNAKMT2AHIF1ACASP7MEN1 | |
| Terbutaline SCHEMBL10535091 | 0.95 | LMNA (0.94) | LMNAKMT2AHIF1ACASP7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-1442751-B1 | Diagnostic imaging technique | GE HEALTHCARE AS (NO) | 2007-06-20 | — | — | EP | disclosed |
| EP-1442751-A1 | Method of imaging | Amersham Health AS (NO) | 2004-08-04 | — | — | EP | disclosed |
| EP-0977600-B1 | CONTRAST AGENTS TARGETTING RECEPTORS ASSOCIATED WITH ANGIOGENESIS | AMERSHAM HEALTH AS (NO) | 2004-06-30 | — | — | EP | disclosed |
| US-20040009122-A1 | Contrast agents | AMERSHAM HEALTH AS (NO) | 2004-01-15 | — | — | US | disclosed |
| US-6610269-B1 | Disease state imaged using a targeted contrast agent of the formula V-L-R, where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker, R is a macromolecular or particulate label | AMERSHAM HEALTH AS (NO) | 2003-08-26 | — | — | US | disclosed |
| EP-0977600-A2 | CONTRAST AGENTS | NYCOMED IMAGING A/S (NO) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998047541-A1 | CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009122-A1 | Contrast agents | FLT1, FLT4, KDR | ADRB2 995/4885LMNA 1139/4885KMT2A 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.